Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for Epistaxis in HHT
NCT03954782Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Epistaxis duration assessed on epistaxis grids at 12 weeks. Started Jun 2020; status: completed.
02
Drugs
nintedanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03954782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954782.